Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Barrow | $655,000 | $0 | $11,719,750 | $0 | $378,263 | $0 | $14,429 | $12,767,442 |
| Chief Executive Officer | ||||||||
| Brandi Roberts | 288,750 | 0 | 1,815,000 | 2,890,889 | 121,322 | 0 | 401 | 5,116,362 |
| Chief Financial Officer | ||||||||
| Daniel Karlin | 510,000 | 0 | 3,262,525 | 0 | 214,200 | 0 | 14,533 | 4,001,258 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Robert Barrow | $12,767,442 | — | — | — |
| Brandi Roberts | 5,116,362 | — | — | — |
| Daniel Karlin | 4,001,258 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robert Barrow | RSU | 375,000 | — | $5,021,250 |
| Robert Barrow | RSU | 284,375 | — | 3,807,781 |
| Robert Barrow | RSU | 125,000 | — | 1,673,750 |
| Daniel Karlin | RSU | 100,000 | — | 1,339,000 |
| Daniel Karlin | RSU | 93,438 | — | 1,251,135 |
| Brandi Roberts | RSU | 62,500 | — | 836,875 |
| Daniel Karlin | RSU | 39,063 | — | 523,054 |
| Robert Barrow | RSU | 7,583 | — | 101,536 |
| Daniel Karlin | RSU | 3,958 | — | 52,998 |
| Robert Barrow | Option | 216,667 | 4.98 | — |
| Robert Barrow | Option | 12,125 | 17.72 | — |
| Brandi Roberts | Option | 500,000 | 7.26 | — |
| Daniel Karlin | Option | 81,250 | 4.98 | — |
| Daniel Karlin | Option | 5,208 | 17.72 | — |
The compensation philosophy is based on providing equitable and highly competitive compensation to attract, motivate, and retain top talent, directly linking short-term compensation to measurable corporate goals, and providing a highly competitive long-term incentive structure aligned with shareholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | — |
| Anti-hedging | — |
| Anti-pledging | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Carol A. ValloneIndependent · Audit · Compensation | $97,000 | $0 | $399,827 | — | — | $496,827 |
| Andreas KrebsIndependent · Audit · Nominating and Corporate Governance | 85,000 | 0 | 399,827 | — | — | 484,827 |
| David GryskaIndependent · Audit (Chair) | 59,000 | 0 | 399,827 | — | — | 458,827 |
| Dr. Suzanne BruhnIndependent · Compensation (Chair) · Nominating and Corporate Governance | 58,000 | 0 | 399,827 | — | — | 457,827 |
| Dr. Roger CrystalIndependent · Compensation · Nominating and Corporate Governance (Chair) | 57,000 | 0 | 399,827 | — | — | 456,827 |
| Robert BarrowEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $356,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $356,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Definium Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Definium Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Definium Therapeutics | 2025 | Robert Barrow | $655,000 | $11,719,750 | $0 | $378,263 | $12,767,442 |
| 2 | Relmada Therapeutics, Inc. | 2025 | Sergio Traversa | 787,787 | — | 4,951,301 | — | 8,892,633 |
| 3 | Kalvista Pharmaceuticals, Inc. | 2024 | Benjamin Palleiko | 580,441 | 5,486,659 | 302,468 | 0 | 6,772,197 |
| 4 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 5 | Humacyte, Inc. | 2025 | Laura Niklason | 633,606 | 0 | 4,332,725 | 0 | 5,234,908 |
| 6 | Solid Biosciences Inc. | 2025 | Alexander Cumbo | 650,988 | 2,318,275 | 1,792,397 | 0 | 5,223,442 |
| 7 | Neumora Therapeutics, Inc. | 2025 | Paul Berns | 700,000 | 0 | 3,326,181 | 504,000 | 4,562,461 |
| 8 | AtaiBeckley Inc. | 2025 | Srinivas Rao | 629,200 | 0 | 3,316,737 | 0 | 4,420,555 |
| 9 | Anavex Life Sciences Corp | 2024 | Christopher Missling | 700,000 | 0 | 1,927,600 | 0 | 2,783,700 |
| 10 | Lineage Cell Therapeutics, Inc. | 2025 | Brian Culley | 691,800 | 0 | 882,970 | 518,900 | 2,111,170 |
| 11 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 12 | Annexon, Inc. | 2025 | Patrick Smith | 31,201 | 0 | 0 | 0 | 40,001 |
| — | Compass Pathways plc | — | — | — | — | — | — | not in coverage universe |
| — | Praxis Precision Medicines, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | MeiraGTx Holdings plc | — | — | — | — | — | — | not in coverage universe |
| — | Larimar Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Fulcrum Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Stoke Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Trevi Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | LeonaBio, Inc. (f/k/a Athira Pharma) | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Definium Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Anavex Life Sciences Corp | 20% | Options 100 | not disclosed | not disclosed |
| Annexon, Inc. | 135.9% | PSU 100 | No | Semler Brossy |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| AtaiBeckley Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Compass Pathways plc | not disclosed | not disclosed | not disclosed | not disclosed |
| Fulcrum Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Humacyte, Inc. | 80% | not disclosed | not disclosed | Aon plc |
| Kalvista Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Larimar Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| LeonaBio, Inc. (f/k/a Athira Pharma) | not disclosed | not disclosed | not disclosed | not disclosed |
| Lineage Cell Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Anderson |
| MeiraGTx Holdings plc | not disclosed | not disclosed | not disclosed | not disclosed |
| Neumora Therapeutics, Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Praxis Precision Medicines, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Relmada Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon Radford |
| Solid Biosciences Inc. | 100% | not disclosed | No | Radford (AON Hewitt) |
| Stoke Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Trevi Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Robert Barrow | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Executive Compensation”. As printed: 12,767,442. Filing ↗machine: span 971469–971479 |
| 2 | Section 01, Brandi Roberts | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Executive Compensation”. As printed: 5,116,362. Filing ↗machine: span 989351–989360 |
| 3 | Section 01, Daniel Karlin | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Executive Compensation”. As printed: 4,001,258. Filing ↗machine: span 1004425–1004434 |
| 4 | Section 08, Carol A. Vallone | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Director Compensation”. As printed: 496,827. Filing ↗machine: span 1324544–1324551 |
| 5 | Section 08, Andreas Krebs | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Director Compensation”. As printed: 484,827. Filing ↗machine: span 1330544–1330551 |
| 6 | Section 08, David Gryska | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Director Compensation”. As printed: 458,827. Filing ↗machine: span 1348650–1348657 |
| 7 | Section 08, Dr. Suzanne Bruhn | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Director Compensation”. As printed: 457,827. Filing ↗machine: span 1336548–1336555 |
| 8 | Section 08, Dr. Roger Crystal | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Director Compensation”. As printed: 456,827. Filing ↗machine: span 1342552–1342559 |
| 9 | Section 08, Robert Barrow | DEF 14A | 2026-04-27 | 0001193125-26-182034 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 09b board cost (computed) | Computed | — | computed | Cash 356,000 + equity 0 + all other 0 = 356,000, summed across the director compensation table rows.machine: formula: Σ = 356,000 |
| 11 | Definium Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182034 | CEO total compensation as printed in Definium Therapeutics's own proxy. As printed: 12,767,442. Filing ↗machine: span 971469–971479 |
| 12 | Relmada Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001213900-26-045192 | CEO total compensation as printed in Relmada Therapeutics, Inc.'s own proxy. As printed: 8,892,633. Filing ↗ |
| 13 | Kalvista Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-08-21 | 0001193125-25-185353 | CEO total compensation as printed in Kalvista Pharmaceuticals, Inc.'s own proxy. As printed: 6,772,197. Filing ↗machine: span 291290–291299 |
| 14 | Arvinas, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028156 | CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930 |
| 15 | Humacyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187449 | CEO total compensation as printed in Humacyte, Inc.'s own proxy. As printed: 5,234,908. Filing ↗machine: span 346967–346976 |
| 16 | Solid Biosciences Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173642 | CEO total compensation as printed in Solid Biosciences Inc.'s own proxy. As printed: 5,223,442. Filing ↗machine: r2 · c25 · span 472915–472924 |
| 17 | Neumora Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161489 | CEO total compensation as printed in Neumora Therapeutics, Inc.'s own proxy. As printed: 4,562,461. Filing ↗machine: r2 · c29 · span 444810–444819 |
| 18 | AtaiBeckley Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016161 | CEO total compensation as printed in AtaiBeckley Inc.'s own proxy. As printed: 4,420,555. Filing ↗machine: r2 · c18 · span 460146–460155 |
| 19 | Anavex Life Sciences Corp, Section 10b CEO total | DEF 14A | 2025-04-25 | 0001731122-25-000607 | CEO total compensation as printed in Anavex Life Sciences Corp's own proxy. As printed: 2,783,700. Filing ↗machine: r1 · c23 · span 229348–229357 |
| 20 | Lineage Cell Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191556 | CEO total compensation as printed in Lineage Cell Therapeutics, Inc.'s own proxy. As printed: 2,111,170. Filing ↗machine: span 377951–377960 |
| 21 | Alector, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 22 | Annexon, Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001628280-26-025521 | CEO total compensation as printed in Annexon, Inc.'s own proxy. As printed: 40,001. Filing ↗machine: t53 · r2 · c14 · span 1677190–1677196 |
| 23 | Section 10a, Arvinas, Inc. reciprocity | DEF 14A | — | 0001628280-26-028156 | Arvinas, Inc.'s most recent proxy was read; its disclosed peer group does not include Definium Therapeutics. Filing ↗ |
| 24 | Section 10a, Alector, Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector, Inc.'s most recent proxy was read; its disclosed peer group does not include Definium Therapeutics. Filing ↗ |
| 25 | Section 10a, Lineage Cell Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-191556 | Lineage Cell Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Definium Therapeutics. Filing ↗ |
| 26 | Section 10a, Annexon, Inc. reciprocity | DEF 14A | — | 0001628280-26-025521 | Annexon, Inc.'s most recent proxy was read; its disclosed peer group does not include Definium Therapeutics. Filing ↗ |
| 27 | Section 10a, Humacyte, Inc. reciprocity | DEF 14A | — | 0001193125-26-187449 | Humacyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Definium Therapeutics. Filing ↗ |